There are a number of reasons to choose LBDDS over conventional formulation approaches when working with poorly soluble compounds. However, the range of lipidic excipients and the abundance of factors that go into determining which combinations of lipids, cosolvents, and surfactants to select makes LBDDS a complex, formulation-dependent technology. Know what criteria to consider when selecting a CMO to handle LBDDS manufacturing.
Gone are the days when medical consumers would settle for just one formulation of a medication. Keeping an eye on some emerging trends that are shaping society and the pharmaceutical industry can help you meet those diverse consumer preferences and potentially extend the lifecycle of their products.
Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency - a key goal for biopharmaceutical production.
Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
3D printing allows drug companies to not only boost efficacy and adherence but also contribute to their brand longevity by expanding and capturing market share with other dosage form options.
This study presents how strategic enhancements to the sparge and agitation systems of Thermo Scientific HyPerforma S.U.B.s have revealed the potential for a three- to four-fold improvement in mixing and mass transfer performance compared to legacy S.U.B. designs.
Learn how a structured 3-step approach can help overcome the challenge of molecular characterization and a limited budget.
How SYLOID FP silica products contribute significantly in mitigating/resolving key challenges such as formulation stability over time and their ability to withstand challenging processing conditions.
The combined adsorption capacity, porosity, particle size, and density of the SYLOID® XDP silicas provide a tool to convert liquid ingredients into free flowing powder.
Grace’s SYLOID® 244 FP silica is highly porous and an excellent solution for converting viscous Simethicone into compressible free flowing powder to make chewable tablets.